LABORATOIRES THEA

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: -

Website: http://www.laboratoires-thea.com/

Clinical Trials

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Phase 2

Recruiting

Conditions: Retinitis Pigmentosa (RP)
Usher Syndrome Type 2
Deaf Blind
Retinal Disease
Eye Diseases, Hereditary
Eye Disorders Congenital
Vision Disorders

Interventions: Drug: Intravitreal Injection of Ultevursen
Other: No intervention, will not receive any active study intervention

First Posted Date: 2024-10-04

Last Posted Date: 2024-12-18

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 81

Registration Number: NCT06627179

Locations: 🇺🇸
Retina Foundation of the Southwest, Dallas, Texas, United States

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension

Phase 2

Active, not recruiting

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: T4090 0.2%
Drug: T4090 0.3%
Drug: Rhopressa®

First Posted Date: 2024-05-01

Last Posted Date: 2024-10-04

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 126

Registration Number: NCT06394973

Locations: 🇺🇸
Arizona Advanced Eye Research Institute, Glendale, Arizona, United States
🇺🇸
Global Research Management, Inc., Glendale, California, United States
🇺🇸
United Medical Research Institute, Inglewood, California, United States

and more 20 locations

Comparison of the Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.

Not Applicable

Not yet recruiting

Conditions: Dry Eye Syndrome

Interventions: Device: Hylo-Forte®
Device: T2769

First Posted Date: 2024-04-19

Last Posted Date: 2024-08-26

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 74

Registration Number: NCT06375499

Comparison of the Performance and Safety of T2769 Versus Vismed® Multi in the Treatment of Moderate to Severe Dry Eye Syndrome

Not Applicable

Recruiting

Conditions: Dry Eye

Interventions: Device: T2769
Device: Vismed® Multi

First Posted Date: 2023-07-28

Last Posted Date: 2024-04-29

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 226

Registration Number: NCT05965778

Locations: 🇫🇷
Gabriel-Montpied University Hospital, Clermont-Ferrand, France

Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.

Not Applicable

Completed

Conditions: Dry Eye

Interventions: Device: T2769

First Posted Date: 2023-07-05

Last Posted Date: 2023-12-20

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 34

Registration Number: NCT05931861

Locations: 🇧🇬
Ambulatory For Group Practice For Specialized Medical Care For Eye Diseases - Dr. Grupchevi, Varna, Bulgaria
🇧🇬
Medical Center "Oxycom", Burgas, Bulgaria
🇧🇬
Medical Center "Vereya", Stara Zagora, Bulgaria

and more 3 locations

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Bimatoprost Ophthalmic

First Posted Date: 2023-02-15

Last Posted Date: 2023-11-14

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 40

Registration Number: NCT05729594

Locations: 🇺🇸
Biotrial, Newark, New Jersey, United States

Clinical Investigation to Evaluate the Tolerance of T10070 on Healthy Volunteers

Not Applicable

Completed

Conditions: Healthy Volunteers

Interventions: Device: T10070, Plastic tube with a roll-on applicator filled with an ointment

First Posted Date: 2022-11-18

Last Posted Date: 2022-12-07

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 39

Registration Number: NCT05622435

Locations: 🇵🇱
Eurofins Dermscan Poland, Gdańsk, Poland

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Phase 3

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost Ophthalmic

First Posted Date: 2022-05-31

Last Posted Date: 2024-07-18

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 684

Registration Number: NCT05397600

Locations: 🇺🇸
Scheie Eye Institute - University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Santa Barbara Eyecare - Santa Barbara, Santa Barbara, California, United States
🇺🇸
Ocala Eye - 3130 Location, Ocala, Florida, United States

and more 60 locations

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

Phase 1

Active, not recruiting

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Kinezodianone R hydrochloride
Drug: Placebo

First Posted Date: 2022-05-25

Last Posted Date: 2024-02-07

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 120

Registration Number: NCT05389267

Locations: 🇺🇸
Dr EL-HARAZI, Glendale, California, United States

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

Phase 2

Terminated

Conditions: Retinitis Pigmentosa
Usher Syndrome Type 2
Retinal Disease
Deaf Blind
Eye Diseases
Eye Disorders Congenital
Vision Disorders
Eye Diseases, Hereditary

Interventions: Drug: QR-421a
Other: Sham-procedure

First Posted Date: 2022-01-04

Last Posted Date: 2024-08-07

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 5

Registration Number: NCT05176717

Locations: 🇺🇸
University of Wisconsin - Madison, Madison, Wisconsin, United States
🇺🇸
Retina Foundation of the Southwest, Dallas, Texas, United States
🇬🇧
Moorfields Eye Hospital, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy